文献速递心力衰竭与心肌病心律失常

心脏再同步治疗在蒽环类药物诱导的心肌病中的应用

Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy.
PubMed 文献 · Heart · 2021-09-06

本研究回顾性分析2003-2019年单中心34例接受心脏再同步治疗(CRT)的蒽环类药物诱导心肌病(AIC)患者,并与369例其他非缺血性心肌病(NICM)患者进行倾向匹配比较。结果显示AIC患者CRT术后左室射血分数(LVEF)从21.8%±7.6%提升至30.4%±13.0%(p<0.001),且LVEF提升≥10%者生存更优(p=0.01);AIC与其他NICM病因在LVEF改善和长期生存上无显著差异。

要点

  • CRT术后LVEF提升≥10%的AIC患者长期生存显著优于未达此标准者。
  • AIC不是CRT植入的禁忌,其左室重构和生存获益与其他NICM相当。

核心结论

  • AIC患者接受CRT后左室重构改善程度与其他病因NICM相似。
  • CRT术后LVEF提升≥10%的AIC患者长期死亡率优于未 responders。

研究设计与样本

  • 单中心回顾性队列研究,纳入2003-2019年接受CRT植入的AIC患者34例。
  • 与同期369例其他病因NICM患者进行倾向匹配分析。

主要发现

  • AIC患者平均年龄60.5±12.7岁,基线LVEF 21.7%±7.4%。
  • CRT术后9.6±8.1个月,LVEF从21.8%±7.6%升至30.4%±13.0%(p<0.001)。
  • 42.5%的AIC患者CRT术后LVEF提升≥10%,其生存显著优于未提升者(p=0.01)。
  • 倾向匹配分析显示AIC与其他NICM在LVEF改善和长期生存上无显著差异。

关键数值与推荐

  • AIC患者CRT术后LVEF提升≥10%定义为responder,占队列42.5%。
  • Responder较non-responder长期生存显著更优(p=0.01)。

临床怎么用

  • 对于蒽环类药物诱导的心肌病患者,若符合CRT适应证可考虑植入。
  • CRT术后LVEF提升≥10%可作为预测长期生存改善的指标。

局限性

  • 回顾性单中心研究,AIC样本量较小(34例)。
  • 未报告CRT植入的具体适应证和并发症信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chemotherapy-induced cardiomyopathy has been increasingly recognised as patients are living longer with more effective treatments for their malignancies. Anthracyclines are known to cause left ventricular (LV) dysfunction. While heart failure medications are frequently used, some patients may need consideration for device-based therapies such as cardiac resynchronisation therapy (CRT). However, the role of CRT in anthracycline-induced cardiomyopathy (AIC) is not well understood. METHODS: We performed a retrospective review of all patients undergoing CRT implantation at our centre from 2003 to 2019 with a diagnosis of AIC. The LV remodelling and survival outcomes of this population were obtained and then compared with consecutive patients with other aetiologies of non-ischaemic cardiomyopathy (NICM). RESULTS: A total of 34 patients underwent CRT implantation with a diagnosis of AIC with a mean age of 60.5±12.7 years, left ventricular ejection fraction (LVEF) of 21.7%±7.4%, and 11.3±7.5 years and 10.2±7.4 years from cancer diagnosis and last anthracycline exposure, respectively. At 9.6±8.1 months after CRT implantation, there was an increase of LVEF from 21.8%±7.6% to 30.4%±13.0% (p<0.001). Patients whose LVEF increased by at least 10% post-CRT implant (42.5% of cohort) survived significantly longer than patients who failed to improve their LVEF by that amount (p=0.01). A propensity matched analysis between patients with AIC and 369 consecutive patients with other aetiologies of NICM who underwent CRT implantation during the same period revealed no significant differences in improvement in LVEF or long-term survival. CONCLUSIONS: Patients with AIC undergo LV remodelling with CRT at rates similar to other aetiologies of NICM. Furthermore, AIC post-CRT responders have a favourable long-term mortality compared with non-responders.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Patel D, Kumar A, Moennich LA, et al. Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart. 2021. PMID: 34489312. doi:10.1136/heartjnl-2020-318333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。